1st Quarter - Report
VENN STRATEGIES for BIOMARIN PHARMACEUTICAL, INC.
Firm
Income
$30,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Tax policy affecting bio pharmaceutical companies
| Lobbyist | Covered position, as disclosed |
|---|---|
| JACK BAER | — |
| TIM CAREY | — |
| NOELLE MONTANO | — |
| AMY L REDL | — |
| STEPHANIE SILVERMAN | — |
Health Issues HCR
Orphan drugs and rare diseases, matters related to drug reimbursement policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| JACK BAER | — |
| TIM CAREY | — |
| NOELLE MONTANO | — |
| AMY L REDL | — |
| STEPHANIE SILVERMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.